1- Laddha NC, Dwivedi M, Begum R. Increased tumor necrosis factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS ONE 2012; 7 :e52298.
2- Ezzedine, K., Lim, H. W., Suzuki, T., Katayama, I., Hamzavi, I., Lan, C. C. E., Goh, B. K., Anbar, T., Silva de Castro, C., Lee, A. Y.,Vitiligo Global Issue Consensus Conference Panelists. (2012). Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell &Melanoma Research 25(3),E1–E13.doi:10.1111/j.1755- 148X.2012.00997.x
3- Roberta Colucci, Federica Dragoni, Silvia Moretti, "Oxidative Stress and Immune System in Vitiligo and Thyroid Diseases", Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 631927, 7 pages, 2015. https://doi.org/10.1155/2015/631927
4- Kastrup, J. (2012).Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology, 217(5), 483–491. doi:10.1016/j.imbio.2011.04.007
5- Simsek, I., Meric, C., Erdem, H., Pay, S., Kilic, S., & Dinc, A. (2008). Accuracy of recall of the items included in disease activity forms of Behçet’s disease: comparison of retrospective questionnaires with a daily telephone interview. Clinical Rheumatology, 27(10), 1255– 1260. doi:10.1007/s10067-008-0899-8
6- Rath, T., Roderfeld, M., Güler, C., Wenzel, C., Graf, J., Beitinger, F., Roeb, E., & Zachoval, R. (2011). YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology, 46(11), 1369–1380. doi:10.3109/00365521.2011.613949
7- Ahmed, S. F., Attia, E. A. S., Saad, A. A., Sharara, M., Fawzy, H., & El Nahrery, E. M. A. (2015). Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. Journal of the European Academy of Dermatology and Venereology, 29(4), 682–688. doi:10.1111/jdv.12653
8- Erfan, G., Guzel, S., Alpsoy, S., Rifaioglu, E. N., Kaya, S., Kucukyalcın, V., Topcu, B., & Kulac, M. (2015). Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Molecular and Cellular Biochemistry, 400(1–2), 207–212. doi:10.1007/s11010-014-2277-y
9- Lee C.G, C. A. Da Silva, C. S. Dela Cruz et al.(2011): “Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury,” Annual Review of Physiology, vol. 73, pp. 479–501.
10-Hartl, D., Lee, C. G., Da Silva, C. A., Chupp, G. L., & Elias, J. A. (2009). Novel biomarkers in asthma: chemokines and chitinase-like proteins. Current Opinion in Allergy and Clinical Immunology, 9(1), 60–66. doi:10.1097/ACI.0b013e32831f8ee0
11- Saba, M., Sharif, M. R., Akbari, H., Nikoueinejad, H., & Ramazani Jolfaii, M. (2014). YKL-40 in Asthma and its correlation with different clinical parameters. Iranian Journal of Allergy, Asthma, and Immunology,13(4),271–7. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/24659163
12- Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., … Akdis, C. A. (2016). Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 138(2), 336–349. doi:10.1016/j.jaci.2016.06.010
13- Ezzedine, Khaled, Eleftheriadou, V., Whitton, M., & van Geel, N. (2015). Vitiligo. The Lancet, 386(9988), 74–84. doi:10.1016/S0140- 6736(14)60763-7
14-Rashighi, Mehdi, & Harris, J. E. (2017). Vitiligo Pathogenesis and Emerging Treatments. Dermatologic Clinics, 35(2), 257–265. doi:10.1016/j.det.2016.11.014
15- Singh, S., Khandpur, S., Sharma, V. K., & Ramam, M. (2013). Comparison of efficacy and side-effect profile of oral PUVA vs. oral PUVA sol in the treatment of vitiligo: a 36-week prospective study. Journal of the European Academy of Dermatology and Venereology, 27(11), 1344–1351. doi:10.1111/jdv.12002
16- Mollet, I., van Geel, N., & Lambert, J. (2010). Autoimmune/inflammatory and other diseases associated with vitiligo. In Vitiligo (pp. 79-90). Springer, Berlin, Heidelberg.
17- van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., Wietze van der Veen, J. P., Bos, J. D., Melief, C. J. M., Vyth-Dreese, F. A., & Luiten, R. M. (2009). Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients. Journal of Investigative Dermatology, 129(9), 2220–2232. doi:10.1038/jid.2009.32
18- Hakala B.E, C. White, and A. D. Recklies(2000): “Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family,” Journal of Biological Chemistry, vol. 268, no. 34, pp.2581-25803.
19- Jefri M, Huang Y-N, Huang W-C, Tai C-S, Chen W-L (2015): YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer .15:59
20- Kazakova, M. H., & Sarafian, V. S. (2017). YKL‐40: The Search for New Biomarkers in Rheumatoid Arthritis. New Developments in the Pathogenesis of Rheumatoid Arthritis, 139.
21- Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, et al. (2000): Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 32:911-920 .
22- Aydın, B. (2015). Alopesi areata'lı (AA) hastalarda serum YKL-40 ve TGF-β1 düzeyinin değerlendirilmesi (Master's thesis, Namık Kemal Üniversitesi)
23- Bilen, H., Altinkaynak, K., Sebin, E., Aksoy, H., & Akcay, F. (2016). Serum YKL-40 and MDA levels in Behçet disease. J Pak Med Assoc, 66(10), 1299-30
24- Claudia Deutschmann, Mandy Sowa, Jayaseelan Murugaiyan, Uwe Roesler, et al Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn’s Disease, Journal of Crohn's and Colitis, Volume 13, Issue 7, July 2019, Pages 894–904, https://doi.org/10.1093/ecco-jcc/jjz01
)
View on SCiNiTO